Traws Pharma Inc. Common Stock (TRAW)

FairStock Score: 73/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Traws Pharma as a Graham-style analyst, not a speculator. It is a clinical-stage biopharmaceutical company with four employees, developing small molecules for respiratory viral diseases and cancer. That is not a business with a durable moat today; it is a collection of experimental programs whose value depends on clinical data and regulatory outcomes I cannot verify from the financial statements. The numbers are unattractive. FairStock reports a $6.3 million market cap at the 2026-10-13 close of $0.41, a P/E of -0.24, P/B of 3.73, ROE of -433.36%, and ROCE of -99.40%. Trailing free cash flow is -$19.4 million, a FCF yield of -308.4%, which dwarfs the market cap. Filed results show in fiscal year 2024, the year ended 2024-12-31, revenue of $226,000 and a net loss of $166.5 million; in fiscal year 2025, the year ended 2025-12-31, revenue of $2.8 million and net income of $9.2 million, which is why FairStock labels it a TURNAROUND - Returned to profit after a loss within the last 3 years. But that turnaround did not persist: in fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $7.1 million; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $3.1 million. In fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $2.7 million and net loss was $915,000. Recent quarters show revenue as n/a. Financial health is poor by the supplied scores: Piotroski 2/9 and Altman Z-Score -79.16. D/E is not available. Valuation is almost impossible on earnings because earnings are negative. A low absolute price and a 52-week range of $0.41 to $3.23 do not create safety; they often reflect financing and trial risk. I would require a much clearer balance sheet, revenue, and margin of safety before calling this a value opportunity.

In plain English: Traws Pharma is a very small clinical-stage biotech that is trying to develop experimental medicines for respiratory viruses and cancer. The business looks weak right now: it has almost no steady revenue and has reported large losses in recent quarters. At 41 cents a share, the price may look low, but compared with the company's tiny sales and ongoing losses, it does not look clearly cheap on ordinary business numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer